Treatment of Canine Demodicosis: Evidence-Based Clinical Approach

Treatment of canine demodicosis depends on disease severity, patient factors, and presence of underlying conditions. A structured, evidence-based approach is essential for achieving clinical and parasitological cure. 

General Treatment Considerations 

Demodicosis ranges from mild localized to severe generalized disease. Mild localized cases may resolve spontaneously in most dogs, although the proportion of generalized cases undergoing spontaneous remission remains unclear due to limited robust data¹. 

In juvenile dogs, treatment of demodicosis and any secondary bacterial infection is often sufficient. In contrast, adult-onset disease may warrant investigation for underlying immunosuppressive conditions, although a cause may not always be identified². 

Monitoring and Duration of Therapy 

Treatment response should be assessed both clinically and microscopically: 

• Patients should be re-examined monthly 

• Skin scrapings should be taken from the same sites at each visit 

• Mite numbers and immature stages should progressively decrease 

If no improvement is observed, a change in therapy should be considered¹. 

Miticidal therapy should be continued four weeks beyond the second set of negative monthly scrapings to reduce recurrence risk³. Long-term follow-up (up to 12 months) may be required before considering a patient cured¹. 

Management of Secondary Bacterial Infections 

Secondary bacterial infections are common. 

• Topical antimicrobial therapy alone may be sufficient in mild to moderate cases 

• Systemic antibiotics may not always be required 

• In severe infections or when rod-shaped bacteria are present, culture and sensitivity testing is recommended 

Judicious use of antibiotics is advised due to increasing antimicrobial resistance⁴. 

Amitraz 

Amitraz has been a long-standing treatment for generalized demodicosis^1,5. 

• Applied as a leave-on rinse 

• Recommended concentrations: 0.025%–0.06% weekly or biweekly 

• Clipping may improve efficacy in long-haired dogs 

Treatment requires proper application and safety precautions, including use in well-ventilated areas. Adverse effects in dogs may include sedation, gastrointestinal signs, and cardiovascular changes. Smaller breeds may be at increased risk of toxicity¹. 

Macrocyclic Lactones 

Ivermectin 

• Commonly used at 300–600 µg/kg orally once daily¹ 

• Requires gradual dose escalation 

• Risk of neurotoxicity, especially in MDR1-mutant breeds 

Adverse effects may include mydriasis, ataxia, seizures, and coma. There is no specific antidote, and supportive care is required in cases of toxicity¹. 

Milbemycin Oxime 

• Used at 0.5–2 mg/kg daily^1,6 

• Higher doses may improve efficacy 

• Generally well tolerated, though caution is advised in MDR1-mutant dogs 

Moxidectin 

• Oral and topical formulations available 

• Topical moxidectin/imidacloprid may be effective in mild to moderate cases^1,7 

• Dose-dependent efficacy observed with more frequent application 

Doramectin 

• Administered weekly (0.6 mg/kg subcutaneously)^1,8 

• Demonstrates good efficacy with relatively low incidence of adverse effects 

Gradual dose escalation is recommended for systemic macrocyclic lactones to identify sensitive individuals¹. 

Isoxazolines 

Isoxazolines (e.g., fluralaner, afoxolaner, sarolaner, lotilaner) act by inhibiting ligand-gated chloride channels in parasites, leading to mite death⁹. 

Clinical studies demonstrate: 

• Rapid and substantial reduction in mite counts 

• High rates of parasitological cure 

• Generally favorable safety profiles 

These agents offer convenient dosing schedules, which may improve compliance. 

Treatment Outcomes and Recurrence 

• Two-thirds of dogs failing initial therapy may respond to a change in treatment 

• Recurrence can occur, but many cases respond to re-treatment 

• Follow-up beyond treatment completion is recommended 

Clinical Relevance 

Effective management of demodicosis requires: 

• Appropriate selection of miticidal therapy 

• Regular monitoring using skin scrapings 

• Judicious management of secondary infections 

• Consideration of underlying disease in adult-onset cases 

A structured and individualized treatment approach may improve outcomes and reduce recurrence risk. 

References 

1. Mueller RS, Rosenkrantz W, Bensignor E, Karaś‐Tęcza J, Paterson T, Shipstone MA. Diagnosis and treatment of demodicosis in dogs and cats: Clinical consensus guidelines of the World Association for Veterinary Dermatology. Veterinary dermatology. 2020 Feb;31(1):4-e2. https://ebvminpractice.org/wp-content/uploads/2025/09/veterinary-dermatology-2020-mueller-diagnosis-and-treatment-of-demodicosis-in-dogs-and-cats.pdf

2. Chudzicka-Strugała I, Gołębiewska I, Brudecki G, Elamin W, Zwoździak B. Demodicosis in different age groups and alternative treatment options—A review. Journal of Clinical Medicine. 2023 Feb 19;12(4):1649. https://www.mdpi.com/2077-0383/12/4/1649

3. Mueller RS, Rosenkrantz W, Bensignor E, Karaś-Tęcza J, Paterson T, Shipstone MA. WAVD Clinical consensus guidelines for demodicosis. Rosenkrantz, E. Bensignor,[et al.].—2018. 2018. https://wavd.org/wp-content/uploads/clinical-consensus-guidelines-demodicosis.docx

4. Morris DO, Loeffler A, Davis MF, Guardabassi L, Weese JS. Recommendations for approaches to meticillin‐resistant staphylococcal infections of small animals: diagnosis, therapeutic considerations and preventative measures. Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. Veterinary dermatology. 2017 Jun;28(3):304-e69. https://doi.org/10.1111/vde.12444

5. Yadav SN, Boro PK, Bordoloi G, Nath AJ, Ahmed N, Thakuria P. Individual and combined anti-demodicosis effect of ivermectin and amitraz in the treatment of natural canine demodicosis-a clinical study. https://vetpract.in/themes/uploads/contents/192d8c77d0a29d8fcca43a35ca28f641.pdf

6. Romero-Núñez C, Guiliana Bautista-Gómez L, Sheinberg G, Martín A, Romero A, Flores A, Heredia R, Miranda L. Efficacy of Afoxolaner Plus Milbemycin Oxime in the Treatment of Canine Demodicosis. International Journal of Applied Research in Veterinary Medicine. 2019 May 1;17(2). https://jarvm.com/articles/Vol17Iss1/Vol17%20Iss1%20Gomez.pdf

7. Fourie JJ, Meyer L, Thomas E. Efficacy of topically administered fluralaner or imidacloprid/moxidectin on dogs with generalised demodicosis. Parasites & vectors. 2019 Jan 25;12(1):59. https://link.springer.com/content/pdf/10.1186/s13071-018-3230-9.pdf

8. Malik NS, Siddiqui MF, Sakhare MP, Rajurkar SR, Yeotikar PV, Kalwaghe ST, Shafi TA, Chepte SD, Ali SS, Shaikh SR. Assessment of the Therapeutic Efficacy of Doramectin with and Without Levamisole in Managing Canine Demodicosis. Indian Journal of Animal Research.;1:5. http://arccarticles.s3.amazonaws.com/OnlinePublish/Final-article-attachemnt-with-doi-B-5130-6089603e9087340b9bdcbbb1.pdf

9. Zhou X, Hohman AE, Hsu WH. Current review of isoxazoline ectoparasiticides used in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics. 2022 Jan;45(1):1-5. https://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjvp.12959